Xiao-Yan Qin1, Tang Li, Li Yan, Qing-Shan Liu, Yu Tian. 1. Laboratory of Biotechnology and State Key Laboratory of Chinese ethnic minority traditional medicine, College of Life& Environmental Science, Minzu University of China, Beijing, China. bjqinxiaoyan@yahoo.com.cn
Abstract
BACKGROUND AND AIM: Tanshione IIA (TSN) is the major active component of Salvia miltiorrhiza, a traditional Chinese Medicine. TSN protects against antioxidant-induced liver injury, although the exact mechanism is not well understood. MATERIALS AND METHODS: In this study, the protective effects of TSN was examined by enzyme-linked immunosorbent assay (ELISA) and histochemistry of several cytokines. RESULTS: TSN is found to significantly reduce plasma alanin aminotransferase and aspartate amino transferase levels in mice with concanavalin A-induced immune-mediated liver injury. TSN increases T lymphocyte subset CD3+, CD4+ and CD8+ ratios.Also, TSN significantly reduces inflammatory cytokines, including interleukin-2, interleukin-4, interferon-gamma and tumor necrosis factor alpha, while elevates anti-inflammatory cytokine, interleukin-10. CONCLUSIONS: TSN may provide a potential drug candidate for liver injury therapeutics.
BACKGROUND AND AIM: Tanshione IIA (TSN) is the major active component of Salvia miltiorrhiza, a traditional Chinese Medicine. TSN protects against antioxidant-induced liver injury, although the exact mechanism is not well understood. MATERIALS AND METHODS: In this study, the protective effects of TSN was examined by enzyme-linked immunosorbent assay (ELISA) and histochemistry of several cytokines. RESULTS:TSN is found to significantly reduce plasma alanin aminotransferase and aspartate amino transferase levels in mice with concanavalin A-induced immune-mediated liver injury. TSN increases T lymphocyte subset CD3+, CD4+ and CD8+ ratios.Also, TSN significantly reduces inflammatory cytokines, including interleukin-2, interleukin-4, interferon-gamma and tumor necrosis factor alpha, while elevates anti-inflammatory cytokine, interleukin-10. CONCLUSIONS:TSN may provide a potential drug candidate for liver injury therapeutics.
Authors: Dalia Elebeedy; Walid F Elkhatib; Ahmed Kandeil; Aml Ghanem; Omnia Kutkat; Radwan Alnajjar; Marwa A Saleh; Ahmed I Abd El Maksoud; Ingy Badawy; Ahmed A Al-Karmalawy Journal: RSC Adv Date: 2021-09-01 Impact factor: 4.036
Authors: Florent Duval; Jorge E Moreno-Cuevas; María Teresa González-Garza; Carmen Maldonado-Bernal; Delia Elva Cruz-Vega Journal: Int J Inflam Date: 2015-04-14